The stock of Affimed NV (NASDAQ:AFMD) is a huge mover today! The stock decreased 1.96% or $0.05 on November 15, hitting $2.5. About 148,559 shares traded hands or 26.51% up from the average. Affimed NV (NASDAQ:AFMD) has declined 43.71% since April 13, 2016 and is downtrending. It has underperformed by 47.64% the S&P500.
The move comes after 5 months negative chart setup for the $106.01M company. It was reported on Nov, 15 by Barchart.com. We have $2.25 PT which if reached, will make NASDAQ:AFMD worth $10.60 million less.
Affimed NV (NASDAQ:AFMD) Ratings Coverage
Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by BMO Capital Markets given on Tuesday, April 12. The stock of Affimed NV (NASDAQ:AFMD) earned “Hold” rating by Zacks on Thursday, September 3. The stock has “Market Perform” rating given by Leerink Swann on Friday, August 12. As per Thursday, May 19, the company rating was downgraded by Leerink Swann. The firm earned “Sell” rating on Monday, August 10 by Zacks. The rating was maintained by Oppenheimer with “Outperform” on Thursday, August 6. Jefferies maintained the stock with “Hold” rating in Thursday, May 19 report. The stock of Affimed NV (NASDAQ:AFMD) earned “Outperform” rating by Wells Fargo on Friday, December 4. The firm has “Buy” rating given on Thursday, December 10 by Laidlaw. The stock of Affimed NV (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Wednesday, September 9.
According to Zacks Investment Research, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.”
Another recent and important Affimed NV (NASDAQ:AFMD) news was published by Zacks.com which published an article titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?” on August 14, 2015.
AFMD Company Profile
Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.